Cardiol Therapeutics (CRDL) vs Outlook Therapeutics (OTLK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cardiol Therapeutics (CRDL) has outperformed Outlook Therapeutics (OTLK) over the past year, gaining 20.4% versus a loss of 55.2%. Over five years, CRDL leads with a -66.9% price change compared with -98.7% for OTLK. Cardiol Therapeutics is the larger company by market cap ($158.0 million vs $137.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRDL | OTLK |
|---|---|---|
| Share price | $1.30 | $0.564 |
| Market cap | $157.97M | $137.30M |
| 1-day change | -1.52% | -4.41% |
| YTD return | +36.27% | -64.30% |
| 1-year return | +20.37% | -55.24% |
| 5-year return | -66.92% | -98.66% |
| EPS (TTM) | $-0.25 | $-0.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.34 | $2.54 |
| 52-week low | $0.88 | $0.161 |
| Distance from 52-week high | -44.44% | -77.78% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +543.08% | +791.84% |
| Average volume | 1.44M | 13.33M |
| Shares outstanding | 121.51M | 243.45M |
| Employees | 18 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRDL has outperformed OTLK by 75.6 percentage points over the past year.
About Cardiol Therapeutics
CRDL stock →Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
About Outlook Therapeutics
OTLK stock →Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees
CRDL vs OTLK FAQ
Which is bigger, Cardiol Therapeutics or Outlook Therapeutics?
Cardiol Therapeutics (CRDL) is larger, with a market capitalization of $157.97M compared with $137.30M for Outlook Therapeutics (OTLK).
Which stock has performed better over the past year, CRDL or OTLK?
CRDL returned +20.37% over the past 12 months, compared with -55.24% for OTLK (price return, excluding dividends). Past performance does not predict future results.
Are Cardiol Therapeutics and Outlook Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.